AtriCure, Inc.ATRCNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Financials Growth Insiders

Latest News

businesswire.com

AtriCure to Participate in the Citizens Life Sciences Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March 10, 2026, at 1:05 p.m. Eastern Time. Interested parties may access a live audio.

defenseworld.net

AtriCure Q4 Earnings Call Highlights

AtriCure (NASDAQ: ATRC) reported fourth-quarter and full-year 2025 results that management said reflected accelerating growth in several core franchises, improving profitability, and progress on major clinical and product development initiatives. The company also reaffirmed its 2026 outlook for 12% to 14% revenue growth. Full-year and fourth-quarter financial results For full-year 2025, AtriCure posted worldwide revenue of

zacks.com

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

seekingalpha.com

AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript

zacks.com

AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates

AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.

businesswire.com

AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2025 and full year 2025 financial results. “Our 2025 performance reflects strong execution and continued momentum in our business. We delivered 15% revenue growth for the year and strengthened profitability while advancing key innovation and c.

defenseworld.net

AtriCure (NASDAQ:ATRC) Shares Gap Down Following Analyst Downgrade

AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) gapped down before the market opened on Wednesday after JPMorgan Chase and Co. downgraded the stock from an overweight rating to a neutral rating. The stock had previously closed at $37.86, but opened at $34.00. JPMorgan Chase and Co. now has a $36.00 price target on the stock.

zacks.com

Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

businesswire.com

AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financi.

zacks.com

4 High-Efficiency Stocks Poised to Deliver Superior Returns

AtriCure tops a screen of high-efficiency stocks, joined by REV Group, Oceaneering International and Analog Devices after beating industry averages.

gurufocus.com

HARBOR CAPITAL ADVISORS, INC. Buys 4,925 Shares of AtriCure Inc (ATRC)

Summary HARBOR CAPITAL ADVISORS, INC. raised its stake in AtriCure Inc (ATRC) by 17.2%, purchasing 4,925 shares to own 33,564 shares valued at about $1

defenseworld.net

AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to

seekingalpha.com

AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

businesswire.com

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quar.

zacks.com

AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out?

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

defenseworld.net

AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of “Moderate Buy” from Brokerages

AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1 year price objective

defenseworld.net

AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year target

zacks.com

Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Ensign Group (ENSG) have performed compared to their sector so far this year.

zacks.com

AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know

Does AtriCure (ATRC) have what it takes to be a top stock pick for momentum investors? Let's find out.

businesswire.com

AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming J.P. Morgan 44th Annual Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 14, 2026, at 10:30 a.m. Pacific Standard Time. Interested parties may access a live aud.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance